{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 56,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "roadmap",
  "function": "prioritize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a bullseye/concentric circle framework to communicate strategic prioritization of clinical trials.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/46",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.35,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Concentric circles representing Top Priority, Exploratory Combinations, and Potential RASm Opportunities",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fa0c4b4-161b-44e3-bc24-b87b09d30519",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.6,
        "x": 0.36,
        "y": 0.22
      },
      "kind": "list",
      "text": "Top priority to address unmet needs in ~395,000 patients WW. Focus on securing regulatory approval for naporafenib + trametinib in RAS Q61X tissue agnostic solid tumors (SEACRAFT-1) and/or NRASm melanoma (SEACRAFT-2) as soon as possible.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48e7df60-8cd8-40f5-b3ef-a9ba7e3c2356",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.36,
        "y": 0.7
      },
      "kind": "list",
      "text": "Potential RASm opportunities to address unmet needs for ~1.9m patients WW. Ungate potential opportunities in other RASm indications if well tolerated combinations are identified above and/or supported by evolving data.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a682610f-8886-4529-99ca-1edfdf9756fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.6,
        "x": 0.36,
        "y": 0.48
      },
      "kind": "list",
      "text": "Exploratory combos to address unmet needs in ~1.2m patients WW. Explore novel combination(s) in NF1 LOF, RAS G13R and BRAF Class 2 and 3 altered solid tumors (SEACRAFT-3); combos include naporafenib with ERAS-007, ERAS-601, and ERAS-007 + ERAS-601.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8f16d71-fd36-4938-961b-3a7787d095ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Erasca is well positioned to advance naporafenib through a focused development plan that leverages RAS/MAPK pipeline synergies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abc9ef9a-185f-49fd-84e8-defd43600590",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "prioritization-matrix",
      "slug": null,
      "matchId": "51a6b834-33f6-4cd5-bbac-bb28e4c00be8",
      "evidence": "Concentric circles used to define strategic focus areas by priority level.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}